These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36550260)

  • 61. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.
    Silva AC; Ferreira IL; Hayden MR; Ferreiro E; Rego AC
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):34-44. PubMed ID: 28939435
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The absence of the aryl hydrocarbon receptor in the R6/1 transgenic mouse model of Huntington's disease improves the neurological phenotype.
    Angeles-López QD; García-Lara L; Aguirre-Pineda N; Castañeda-Arellano R; Elizondo-Azuela G; Pérez-Severiano F; Segovia J
    Behav Brain Res; 2021 Jun; 408():113230. PubMed ID: 33684424
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
    Chiang MC; Chern Y; Huang RN
    Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
    Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
    Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Focused ultrasound-induced blood brain-barrier opening enhanced vascular permeability for GDNF delivery in Huntington's disease mouse model.
    Lin CY; Tsai CH; Feng LY; Chai WY; Lin CJ; Huang CY; Wei KC; Yeh CK; Chen CM; Liu HL
    Brain Stimul; 2019; 12(5):1143-1150. PubMed ID: 31079989
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease.
    Ban JJ; Chung JY; Lee M; Im W; Kim M
    Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
    Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
    Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.
    Xu X; Tay Y; Sim B; Yoon SI; Huang Y; Ooi J; Utami KH; Ziaei A; Ng B; Radulescu C; Low D; Ng AYJ; Loh M; Venkatesh B; Ginhoux F; Augustine GJ; Pouladi MA
    Stem Cell Reports; 2017 Mar; 8(3):619-633. PubMed ID: 28238795
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity.
    Anglada-Huguet M; Vidal-Sancho L; Giralt A; García-Díaz Barriga G; Xifró X; Alberch J
    Neurobiol Dis; 2016 Nov; 95():22-34. PubMed ID: 26369879
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.
    Jiang M; Wang J; Fu J; Du L; Jeong H; West T; Xiang L; Peng Q; Hou Z; Cai H; Seredenina T; Arbez N; Zhu S; Sommers K; Qian J; Zhang J; Mori S; Yang XW; Tamashiro KL; Aja S; Moran TH; Luthi-Carter R; Martin B; Maudsley S; Mattson MP; Cichewicz RH; Ross CA; Holtzman DM; Krainc D; Duan W
    Nat Med; 2011 Dec; 18(1):153-8. PubMed ID: 22179319
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CAG RNAs induce DNA damage and apoptosis by silencing
    Peng S; Guo P; Lin X; An Y; Sze KH; Lau MHY; Chen ZS; Wang Q; Li W; Sun JK; Ma SY; Chan TF; Lau KF; Ngo JCK; Kwan KM; Wong CH; Lam SL; Zimmerman SC; Tuccinardi T; Zuo Z; Au-Yeung HY; Chow HM; Chan HYE
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33947817
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.
    Tabrizi SJ; Ghosh R; Leavitt BR
    Neuron; 2019 Mar; 101(5):801-819. PubMed ID: 30844400
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
    Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
    Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts.
    Ciesiolka A; Stroynowska-Czerwinska A; Joachimiak P; Ciolak A; Kozlowska E; Michalak M; Dabrowska M; Olejniczak M; Raczynska KD; Zielinska D; Wozna-Wysocka M; Krzyzosiak WJ; Fiszer A
    Cell Mol Life Sci; 2021 Feb; 78(4):1577-1596. PubMed ID: 32696070
    [TBL] [Abstract][Full Text] [Related]  

  • 75. FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat.
    Goold R; Flower M; Moss DH; Medway C; Wood-Kaczmar A; Andre R; Farshim P; Bates GP; Holmans P; Jones L; Tabrizi SJ
    Hum Mol Genet; 2019 Feb; 28(4):650-661. PubMed ID: 30358836
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Precise CAG repeat contraction in a Huntington's Disease mouse model is enabled by gene editing with SpCas9-NG.
    Oura S; Noda T; Morimura N; Hitoshi S; Nishimasu H; Nagai Y; Nureki O; Ikawa M
    Commun Biol; 2021 Jun; 4(1):771. PubMed ID: 34163001
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Therapeutic potential of ginsenoside Rg3 and Rf for Huntington's disease.
    Lee M; Ban JJ; Won BH; Im W; Kim M
    In Vitro Cell Dev Biol Anim; 2021 Jun; 57(6):641-648. PubMed ID: 34128157
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Exosomes from adipose-derived stem cells ameliorate phenotype of Huntington's disease in vitro model.
    Lee M; Liu T; Im W; Kim M
    Eur J Neurosci; 2016 Aug; 44(4):2114-9. PubMed ID: 27177616
    [TBL] [Abstract][Full Text] [Related]  

  • 80. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.